EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing significant challenges, primarily due to a patent cliff and a lack of earnings momentum following the COVID-19 pandemic. Many experts express concerns over its drug pipeline, indicating that the company is in need of a blockbuster drug to drive future growth. While it maintains an attractive dividend yield—ranging from 6.4% to 7%—there is skepticism about the sustainability of this yield if new profitable drugs are not developed soon. The stock’s valuation is seen as low, trading at around 8-10 times earnings, which some experts believe might make it appealing for patient investors. However, the consensus also points to caution due to the industry-wide challenges, including cost-cutting measures and potential government pressure on drug pricing.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
WEAK BUY

Pfizer Inc(PFE)

Jul 24, 2006
Under performed Merck (MRK-N) quite dramatically. Between these two would prefer to own Merck. Making a bit of a bottoming pattern which is constructive. Needs to take out some resistance and if they can break through the $26 level there could be some good upside.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$24.79

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 21, 2006
It has a model price of $33.93 which is a 42% positive differential. Have now sold their consumer division and their balance sheet is going to be a lot smaller. You get the same earnings, but with a smaller balance sheet, which creates, value.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.83

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 12, 2006
The drug sector continues to be weak in general and is a group that has under performed during the last 2/3 years. This one has even under performed the group.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$23.18

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 11, 2006
Have cleared their problems with Cellebrex. Selling their consumers product division for $16 billion cash. This will probably go to share repurchase, increased dividends and acquisition of promising drugs from small companies. Cheap.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.49

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 14, 2006
Great dividend yield. Probably one of the worst performing sectors in the S&P. Lots of cost cutting opportunities. A number of drugs along the pipeline. Trading at around 8/9 X earnings. Pristine balance sheet.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$23.11

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 14, 2006
A real defensive story. Have tremendous internal cash flow. Have a sound dividend and they buy back stocks. A real value play. New drugs coming out are really solid.
Photo of Paul Gardner, CFAPaul Gardner, CFA
Owned
Unlock Rating
$23.11

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 30, 2006
Got rid of a lot of their past problems. The whole drug sector has been a difficult place to be because of pricing pressures, lawsuits, etc. The worst is now over. Large pharmaceuticals are international, so as the US$ drops, their foreign assets increase.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.58

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 26, 2006
A cheap company. The sector is cheap. Really great yield. Expects they will be getting rid of their consumer products division this year, which will give the stock a boost.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$23.58

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 17, 2006
Near 4% yield which is very attractive. Good level to buy. Trading at about 12 X earnings. Gives about 35% return on equity. No debt.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$24.27

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 10, 2006
His model price is $38, a 49% positive differential. Pays a nice fat dividend.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.04

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 09, 2006
Has an ace dividend yield of about 3%. Turning things around. Have a good pipeline. Has there consumer products operation up for sale but thinks they will spin it out to the shareholders. Very little downside risk.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$25.51

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 27, 2006
Owns Teva (TEVA-Q) as a growth stock and owns this one as a value stock. This one seems to be doing things correctly, more so than Merk (MRK-N). Feels the environment has bottomed out and will be getting better. Low risk.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.86

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 30, 2006
Likes the pharmaceutical sector. This one is very cheap. Dividend of 3.5%. Trading at 10 X earnings.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$25.20

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 21, 2006
The fundamental outlook is improving. The worst is behind it. The company is swimming in cash. There could be another dividend increase.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.31

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 15, 2006
Pfizer is a large cap pharma. Probably the largest pharma company in the world. Has suffered along with the rest of the industry. It is well positioned. Very attractive. Good dividend yield. Predicts it will continue to grow 12-15%.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$25.95

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 616 to 630 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica